Unlock instant, AI-driven research and patent intelligence for your innovation.

Combination therapy for treatment of mastocytosis

A technology of mast cells and cells, which can be applied in drug combinations, biochemical equipment and methods, microbial measurement/testing, etc., and can solve problems such as side effects

Pending Publication Date: 2020-11-03
DECIPHERA PHARMA LLC
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently, most tyrosine kinase inhibitors demonstrate only modest efficacy in advanced disease states, with significant side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapy for treatment of mastocytosis
  • Combination therapy for treatment of mastocytosis
  • Combination therapy for treatment of mastocytosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0160]Example 1. Treatment of mutant KIT mast cell lines with Compound A or Compound B inhibits cell proliferation and KIT phosphorylation in mastocytosis cell lines.

[0161] The studies performed showed that treatment with Compound A or Compound B inhibited cell proliferation of mutant KIT HMC1.1KIT V560G and HMC1.2 KIT V560G / D816V mast cell lines. Assays were performed in 96-well plates seeded with 10,000 cells per well. Cells were treated with vehicle control, Compound A or Compound B at various concentrations, allowed to grow for 72 hours, and then assessed for cell proliferation.

[0162] Figure 1A is a graph showing the relative percentage of cell proliferation determined for various concentrations of Compound A. Treatment with Compound A inhibited cell proliferation and growth of HMC1.1 V560G and HMC1.2 V560G / D816V mast cell lines with IC50 values ​​of 2.6nM and 97nM, respectively.

[0163] Figure 1B is a graph showing the relative percentage of cell proliferation...

Embodiment 2

[0164] Example 2. Treatment with the combination of Compound A and trametinib induces apoptosis in mastocytosis cell lines.

[0165] The studies performed showed that combined treatment with compound A and the MEK inhibitor trametinib induced apoptosis in the HMC1.2 KITV560G / D816V mastocytosis cell line. Assays were performed in 96-well plates seeded with 10,000 cells per well. Cells were treated with vehicle control, Compound A, Trametinib or combinations thereof at various concentrations and grown for 24 hours. Apoptosis was assessed by measuring caspase 3 / 7 activity.

[0166] Figure 2A is a graph showing the relative percentage of apoptosis determined for various treatments. Figure 2B is a matrix based on the combination index (CI) method described by Chou and Talalay (1984) and the synergy diagram of computer software by Chou and Martin (2005). CI1 indicates antagonism. Combination treatment with compound A and the MEK inhibitor trametinib unexpectedly showed a stro...

Embodiment 3

[0167] Example 3. Treatment with the combination of Compound B and trametinib induces apoptosis in mastocytosis cell lines.

[0168] Studies were also performed showing that combined treatment with compound B and trametinib induced apoptosis in the HMC1.2KIT V560G / D816V mastocytosis cell line. Assays were performed as described in Example 2. Apoptosis was assessed by measuring caspase 3 / 7 activity.

[0169] Figure 3A is a graph showing the relative percentage of apoptosis determined for various treatments. Figure 3B is a matrix based on the combination index (CI) method described by Chou and Talalay (1984) and the synergy diagram of computer software by Chou and Martin (2005). CI1 indicates antagonism. Combination treatment with compound B and the MEK inhibitor trametinib unexpectedly showed a strong synergy to induce apoptosis in HMC1.2KIT V560G / D816V cells. Figure 3C is the combination index graph of CI, indicating that the combination of compound B and trametinib ha...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure relates to the use of l-[4-bromo-5-[l-ethyl-7-(methylamino)-2-oxo-l,2-dihydro-l,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or l-(5-(7-amino-l-ethyl-2-oxo-l,2-dihydro-l,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor such as for example a RAS, RAF, MEK, or ERK inhibitor for the treatment of mastocytosis.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S.S.N. 62 / 624,453, filed January 31, 2018, which is hereby incorporated by reference in its entirety. Background technique [0003] c-KIT (also known as KIT, CD117, and stem cell factor receptor) is a 145 kDa transmembrane tyrosine kinase protein that acts as a type III receptor. The c-KIT proto-oncogene located on chromosome 4q11-21 encodes the c-KIT receptor, and its ligand is stem cell factor (SCF, gray factor, kit ligand, mast cell growth factor). The receptor has tyrosine protein kinase activity and binding of the ligand SCF results in autophosphorylation of c-KIT and its association with substrates such as phosphatidylinositol 3-kinase (PI3K). Tyrosine phosphorylation by protein tyrosine kinases is particularly important in cell signaling and can mediate signals for major cellular processes such as proliferation, survival, differentiation, apoptosis, attachment, invasion and m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/155A61K31/4375A61P43/00
CPCA61K31/155A61K31/4375A61P43/00A61K2300/00A61K31/553A61K31/506A61K31/404A61K31/4412A61K31/4709A61K31/519A61K31/4523A61K31/4184A61K31/4439C12Q1/6883C12Q2600/156A61K45/06
Inventor D·L·弗林B·D·史密斯A·古普塔
Owner DECIPHERA PHARMA LLC